Biotech Drug Report Generated Aug 28, 2026

tilarganine

GRTX·Galera Therapeutics, Inc.

BEARISH

Drug Impact Rating1/10

Trial Phase: Unknown (legacy asset sold to Biossil.ai)
Time to Market: Unknown — tilarganine is owned by Biossil.ai with no disclosed development timeline.
Why 1/10: No scheduled binary catalyst exists for tilarganine in the next ~12 months. GRTX is delisted and deregistered; the drug was sold to Biossil.ai in 2025. The only remaining value for former shareholders is illiquid, non-transferable CVRs with no guaranteed payment timeline. ImpactScore is 1 — the drug drives no share-price catalyst for a stock that no longer trades publicly.

Actionable Insight ▼ BEARISH

GRTX has been delisted and deregistered — there is no public trading market. Former holders hold only non-transferable CVRs tied to future tilarganine monetization by Biossil.ai, with no guarantee of payment. This is not a tradeable equity position; monitor Biossil.ai developments only if you hold the CVRs.

Price Chart

Loading chart...

Executive Summary

Tilarganine is Galera Therapeutics' legacy drug asset that was sold to Biossil.ai in 2025. Galera itself was acquired by Obsidian Therapeutics in a merger that closed on August 3, 2026, and its stock (GRTX) has been delisted from the OTCQB and deregistered via Form 15-12G. Former Galera shareholders received ~0.7019 shares of the parent company per GRTX share plus Contingent Value Rights (CVRs) entitling them to 80% of net proceeds from tilarganine for 5 years. There is no public trading market for GRTX, and the CVRs are non-transferable with no guarantee of payment. Tilarganine is no longer a publicly-traded biotech catalyst — it is an illiquid contingent right held by former shareholders of a now-private entity.

How It Works

Tilarganine is a legacy oncology drug candidate from Galera Therapeutics. Its precise mechanism is not publicly detailed in available filings, but it was part of Galera's pipeline of dismutase mimetics targeting radiation-induced side effects in cancer treatment. The asset was sold to Biossil.ai in 2025, and Galera no longer develops it.

Trial Status

Tilarganine was sold to Biossil.ai in 2025. Galera's remaining pipeline (avasopasem manganese / GC4419 and GC4711) was retained as "Supportive-Care Products" under the merger with Obsidian Therapeutics. No recent clinical trial data for tilarganine is available in SecBot's ingested databases.

The Two-Sided Case

▲ Bull Case2

Former Galera shareholders hold CVRs entitling them to 80% of net proceeds from tilarganine for 5 years — if Biossil.ai successfully monetizes the asset, CVR payments could provide some residual value.

The merger with Obsidian Therapeutics included a $350M PIPE, providing capital to the combined entity which may support the supportive-care product line (GC4419/GC4711) that is separate from tilarganine.

▼ Bear Case5

GRTX is delisted and deregistered — there is no public trading market for the stock. Former shareholders cannot trade their position.

The CVRs are non-transferable, unregistered, and there is no assurance any payments will be made (per the Aug 4, 2026 8-K filing).

Galera shareholders received only ~1.2% of the combined company post-merger, representing extreme dilution.

Analyst consensus was deeply bearish: 0 Strong Buy, 0 Buy, 4 Hold, 1 Sell, 2 Strong Sell (0% bullish).

The company underwent a 1-for-200 reverse stock split in July 2026, signaling severe financial distress before the merger.

Upcoming Catalysts

No public catalysts — GRTX is delisted and deregistered. The only potential catalyst is a future monetization event for tilarganine by Biossil.ai that would trigger CVR payments to former Galera shareholders.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Galera Therapeutics, Inc. 8-K GRTX ·Originating report

Sources · 4

Hover a chip for the title

1 sec.gov2 sec.gov3 sec.gov4 globenewswire.com